Skip to main content

01.12.2016 | Research article | Ausgabe 1/2016 Open Access

BMC Complementary Medicine and Therapies 1/2016

Hypoglycaemic activity of ethanolic extract of Garcinia mangostana Linn. in normoglycaemic and streptozotocin-induced diabetic rats

BMC Complementary Medicine and Therapies > Ausgabe 1/2016
Muhammad Taher, Tg Muhamad Faris Syafiq Tg Zakaria, Deny Susanti, Zainul Amiruddin Zakaria
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interest.

Authors’ contributions

TMFS, MT, DS, and ZAZ: Planned and designed the experiments. TMFS, MT, and ZAZ: Performed the experiments and drafted the manuscript. TMFS, MT, and DS: Collected the data and conducted statistical analysis. MT, DS, and ZAZ: Provided the chemicals/materials/analysis tools. All authors read and approved the final manuscript.



Various parts of Garcinia mangostana Linn., including its pericarp, have been traditionally used to treat a variety of ailments. In an attempt to establish its medicinal value, the present study was carried out to determine the hypoglycaemic potential of G. mangostana pericarp ethanolic extract (GME) using the streptozotocin-induced (STZ) diabetic rats.


GME at 2,000 mg/kg was subjected to a single-dose acute toxicity test. Following this, the effect of GME (50, 100, and 200 mg/kg) on blood glucose level of normoglycaemic and STZ-induced diabetic rats was determined using single-dose (acute) and multiple-dose (subacute) approaches. Subsequent to the multiple-dose study, serum biochemical analysis and liver histopathological examination were also performed. Throughout the experiments, the effect of GME was compared against the standard hypoglycaemic drug, glibenclamide.


GME was safe for oral consumption up to the dose of 2,000 mg/kg. In both single- and multiple-dose studies, GME significantly (p < 0.05) reduced the blood glucose level in normoglycaemic rats and STZ-induced diabetic rats when compared against the normal control group or diabetic control group, respectively. Moreover, GME also significantly (p < 0.05) increased the rats’ body weight in comparison to the diabetic control group in the multiple-dose study. GME also significantly (p < 0.05) reduced the levels of certain biochemical parameters [i.e., triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), very low density lipoprotein (VLDL), serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), urea, and creatinine] while increased the others [i.e., high density lipoprotein (HDL) and total protein (TP)] when compared to the diabetic control group. Histopathological assessment of the collected liver revealed a mild increase in the population of β-cells in the diabetic rats.


GME exerts the hypoglycaemic activity possibly by increasing the population of insulin-producing β-cells. This activity could be attributed to the presence of antioxidant-bearing tannins like epicathecin, and xanthones like α-mangostin. Thus, the findings demonstrated that GME could be a potential candidate in the management of diabetes owing to its hypoglycaemic effect.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

BMC Complementary Medicine and Therapies 1/2016 Zur Ausgabe